<DOC>
	<DOCNO>NCT02486354</DOCNO>
	<brief_summary>This study single-arm , multi-center , prospective , phase 3 trial aim evaluate efficacy safety icotinib patient locally advance metastatic NSCLC failure least one platinum-based chemotherapy regimen .</brief_summary>
	<brief_title>Icotinib Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically cytologically confirm locally advanced/metastatic ( stage IIIB/stage IV , use American Joint Committee Cancer [ AJCC ] 6th edition tumornodemetastasis [ TNM ] stag system ) NSCLC patient Progressed least one platinumbased chemotherapy regimen entry Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 02 At least one measurable lesion Response Evaluation Criteria Solid Tumors version 1.0 Adequate hematologic biochemical value Patients symptomatic brain metastasis Malignant tumor within previous five year Severe infection ; congestive heart failure Previous treatment drug target EGFR History interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>